Asia-Pacific Injectable Drug Delivery Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025

  • ID: 4583595
  • Report
  • 388 pages
  • Data Bridge Market Research Private Limited
1 of 4

FEATURED COMPANIES

  • Alkermes Plc.,
  • Bespak
  • Eli Lilly and Company,
  • Gerresheimer AG,
  • Pfizer, Inc.,
  • Sandoz,
  • MORE
Asia-Pacific injectable drug delivery market is expected to reach USD 220,922.25 million by 2025.from USD 67,319.56 million in 2017, at a CAGR of 13.9% in the forecast period 2018 to 2025.

The major factors contributing to the growth of the market includes factors such rising cases of chronic diseases and due to rising demand of self-injection devices. On the other hand needle stick injuries and infections may hinder the growth of the market.

The key market players for Asia-Pacific injectable drug delivery market are listed below:
  • Baxter International, Inc.,
  • Becton Dickinson and Company,
  • Gerresheimer AG,
  • Pfizer, Inc.,
  • Schott AG,
  • Alkermes Plc.,
  • Eli Lilly and Company,
  • Sandoz,
  • Terumo Corporation,
  • Teva Pharmaceuticals Industries Ltd.
  • Ypsomed,
  • Bespak
The market is further segmented into:
  • Type
  • Usage Pattern
  • End-User
  • Mode of Administration
  • Distribution Channel
  • Application
  • Geography
The Asia-Pacific injectable drug delivery market is segmented on the basis of type, portability, type, product type, and application, and usage pattern, mode of administration, end user, distribution channel, and geography. The report provides data for 2016 to 2025, 2017 being the current year while 2018 to 2025.is the forecast period for the report.

The Asia-Pacific injectable drug delivery market is segmented based on type into two notable segments; injectable drug delivery device and injectable drug delivery formulation. Injectable drug delivery device market is segmented into conventional injection devices and self-injection devices. The injectable drug delivery formulation is segmented into conventional drug delivery formulation and novel drug delivery formulation. The Injectable drug delivery market is dominated by formulations with 80.0% market share in 2018, growing at a CAGR of 14.0% and will cross USD 178,225.1 million by 2025.

On the basis of application, the market is segmented into autoimmune disease, hormonal disorders, orphan diseases, oncology and others. The autoimmune diseases segment is further sub segmented based on indications into rheumatoid arthritis, multiple sclerosis, Crohn’s disease, psoriasis and others. Hormonal disorders are further segmented into indications such as diabetes, antithrombotic therapy, reproductive health diseases, anemia, osteoporosis and others. The Injectable drug delivery market is dominated by hormonal disorders with 49.4% market share in 2018, growing at a CAGR of 13.7% and will cross USD 107,631.3 million by 2025. However, oncology segment is expected to grow at the highest CAGR of 15.0% in the forecast period, and is expected to reach USD 51,374.1 million in 2025.from USD 14,319.8 million in 2017

On the basis of usage pattern, the market is segmented into curative care, immunization and other usage pattern. The Injectable drug delivery market is dominated by curative care with 94.2% market share in 2018, growing at a CAGR of 13.9% and will cross USD 209,048.6 million by 2025.

On the basis of mode of administration, the market is segmented into skin, circulatory/muskoskeletal, organs and central nervous system. The Injectable drug delivery market is dominated by skin with 50.4% market share in 2018, growing at a CAGR of 14.2% and will cross USD 113,780.0 million by 2025.

On the basis of end users, the market is classified into hospitals and clinics, home healthcare, research laboratories, pharmaceutical and biotechnological companies and others. The Injectable drug delivery market is dominated by hospitals & clinics with 58.0% market share in 2018, growing at a CAGR of 14.0% and will cross USD 129,566.3 million by 2025. However, home healthcare settings segment is expected to grow at the highest CAGR of 15.2% in the forecast period, and is expected to reach USD 44,906.7 million in 2025.from USD 12,286.6 million in 2017

On the basis of distribution channel, the market is classified into hospital pharmacies, pharmacy store, and direct tender and online pharmacy. The Injectable drug delivery market is dominated by direct tenders with 75.5% market share in 2018, growing at a CAGR of 14.2% and will cross USD 170,166.5 million by 2025. However, pharmacy stores segment is expected to grow at the highest CAGR of 14.9% in the forecast period, and is expected to reach USD 28,274.5 million in 2025.from USD 7,975.8 million in 2017.

Based on geography, the Asia-Pacific injectable drug delivery market is segmented into geographical regions, such as,
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
  • Malaysia
  • Singapore
  • Indonesia
  • Taiwan
  • Rest of APAC
Covered in this report

The report covers the present scenario and the growth prospects of the Asia-Pacific injectable drug delivery market for 2018-2025. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Alkermes Plc.,
  • Bespak
  • Eli Lilly and Company,
  • Gerresheimer AG,
  • Pfizer, Inc.,
  • Sandoz,
  • MORE
1 Introduction
1.1 Overview Of Asia-Pacific Injectable Drug Delivery Market
1.2 Currency And Pricing
1.3 Limitation
1.4 Markets Covered

2 Market Segmentation
2.1 Markets Covered
2.2 Geographic Scope
2.3 Years Considered For The Study
2.4 Currency And Pricing
2.5 Research Methodology
2.6 Primary Interviews With Key Opinion Leaders
2.7 Secondary Sources
2.8 Assumptions

3 Market Overview
3.1 Drivers
3.1.1 Rising Cases Of Chronic Diseases
3.1.2 Rising Demand Of Self-Injection Devices
3.1.3 Growth Of Biologics Market
3.1.4 Technological Advancements And Innovations In Drug Delivery Market
3.2 Restraints
3.2.1 Needlestick Injuries And Infections
3.2.2 High Cost Of Development
3.2.3 Strict Regulatory Framework
3.3 Opportunity
3.3.1 Increasing Demand For Generic And Biosimilar Drugs
3.3.1.1 Generics
3.3.1.2 Biosimilars
3.3.2 Increasing Demand For Contraceptive Injectables
3.3.3 Increasing Demand For Self-Administration Of Drugs
3.4 Challenges
3.4.1 Alternative Route Of Drug Administration
3.4.2 Product Recall
3.4.3 Stability Of Products
3.4.4 Sterility Of Injections

4 Executive Summary

5 Premium Insights

6 Asia-Pacific Injectable Drug Delivery Market, By Type
6.1 Overview
6.2 Injectable Drug Delivery Devices
6.2.1 Conventional Injection Devices
6.2.1.1 Conventional Injection Devices, By Material
6.2.1.1.1 Glass
6.2.1.1.2 Plastic
6.2.1.2 Conventional Injection Devices, By Product
6.2.1.2.1 Fillable Syringes
6.2.1.2.2 Prefilled Syringes
6.2.1.3 Conventional Injection Devices, By Usability
6.2.1.3.1 Reusable Syringes
6.2.1.3.2 Disposable Syringes
6.2.2 Self Injection Devices
6.2.2.1 Needle Free Injectors (Nfi)
6.2.2.2 Needle Free Injectors, By Product
6.2.2.2.1 Fillable Needle-Free Injectors
6.2.2.2.2 Prefilled Needle-Free Injectors
6.2.2.3 Needle Free Injectors, By Technology
6.2.2.3.1 Jet Based Needle Free Injectors:
6.2.2.3.2 Spring Based Needle Free Injectors:
6.2.2.3.3 Laser Based Needle Free Injectors:
6.2.2.3.4 Vibration Based Needle Free Injectors:
6.2.2.4 Needle Free Injectors, By Usability
6.2.2.4.1 Reusable Needle-Free Injectors
6.2.2.4.2 Disposable Needle-Free Injectors
6.2.2.5 Auto Injectors
6.2.2.6 Auto Injectors, By Product
6.2.2.6.1 Fillable Auto Injectors
6.2.2.6.2 Pre-Filled Autoinjectors
6.2.2.7 Auto Injectors, By Technology
6.2.2.7.1 Automated Auto Injectors
6.2.2.7.2 Manual Auto Injectors
6.2.2.8 Auto Injectors, By Design
6.2.2.8.1 Standardized Auto Injectors
6.2.2.8.2 Automated Autoinjectors
6.2.2.9 Auto Injectors, By Usability
6.2.2.9.1 Reusable Autoinjectors
6.2.2.9.2 Disposable Autoinjectors
6.2.2.10 Pen Injectors
6.2.2.11 Pen Injectors, By Product
6.2.2.11.1 Single Chambered Pen Injectors
6.2.2.11.2 Dual Chambered Pen Injectors
6.2.2.12 Pen Injectors, By Design
6.2.2.12.1 Standard Pen Injectors
6.2.2.12.2 Customized Pen Injectors
6.2.2.13 Pen Injectors, By Usability
6.2.2.13.1 Reusable Pen Injectors
6.2.2.13.2 Disposable Pen Injectors
6.2.2.14 Wearable Injectors
6.2.2.14.1 Other Devices
6.3 Injectable Drug Delivery Formulation
6.3.1 Conventional Drug Delivery Formulations
6.3.1.1 Solutions
6.3.1.2 Reconstituted/Lyophilized Formulations
6.3.1.3 Suspensions
6.3.1.4 Emulsions
6.3.2 Novel Drug Delivery Formulations
6.3.2.1 Colloidal Dispersions
6.3.2.1.1 Niosomes
6.3.2.1.2 Liposomes
6.3.2.1.3 Polymeric Mixed Micelles
6.3.2.1.4 Nanoparticles
6.3.2.1.5 Nanosuspensions
6.3.2.1.6 Nanoemulsions/Microemulsions
6.3.2.1.7 Solid Lipid Nanoparticles
6.3.2.2 Microparticles
6.3.2.2.1 Microspheres
6.3.2.2.2 Microcapsules
6.3.2.3 Long Acting Injection Formulation

7 Asia-Pacific Injectable Drug Delivery Market, By Application
7.1 Overview
7.2 Asia-Pacific Injectable Drug Delivery Market, By Application
7.3 Hormonal Disorders
7.3.1 Injectable Drugs For Diabetes
7.3.2 Injectable Drugs For Anemia
7.3.3 Injectable Drugs For Reproductive Health Disease
7.3.4 Injectable Drugs For Antithrombotic/Thrombolytic Therapy
7.3.5 Injectable Drugs For Osteoporosis
7.3.6 Injectable Drugs For Growth Hormone Disorders (Ghd)
7.4 Oncology
7.5 Autoimmune Diseases
7.5.1 Injectable Drugs For Rheumatoid Arthritis
7.5.2 Injectable Drugs For Multiple Sclerosis
7.5.3 Injectable Drugs For Crohn’S Diseases
7.5.4 Injectable Drugs For Psoriasis
7.5.5 Injectable Drugs For Other Autoimmune Diseases
7.6 Orphan Disease
7.7 Other Applications
7.7.1 Injectable Drugs For Pain Management
7.7.2 Injectable Drugs For Allergy Treatment
7.7.3 Injectable Drugs For Aesthetic Treatments
7.7.4 Injectable Drugs For Hepatitis C
7.7.5 Injectable Drugs For Hemophilia

8 Asia-Pacific Injectable Drug Delivery Market, By Usage Pattern
8.1 Overview
8.2 Curative Care
8.3 Immunizations
8.4 Other Usage Pattern

9 Asia-Pacific Injectable Drug Delivery Market, By Mode Of Administration
9.1 Overview
9.2 Skin
9.3 Circulatory/ Muskoskeletal
9.4 Organs
9.5 Central Nervous System

10 Asia-Pacific Injectable Drug Delivery Market, By End User
10.1 Overview
10.2 Hospitals And Clinics
10.3 Home Healthcare Settings
10.4 Research Laboratories
10.5 Pharmaceutical And Biotechnological Companies
10.6 Other End Users

11 Asia-Pacific Injectable Drug Delivery Market, By Distribution Channel
11.1 Overview
11.1.1 Hospital Pharmacy
11.1.2 Pharmacy Stores
11.1.3 Direct Tender
11.1.4 Online Pharmacy

12 Asia-Pacific Injectable Drug Dilivery Market By Geography
12.1 Asia-Pacific
12.1.1 Japan Injectable Drug Delivery Market
12.1.2 China Injectable Drug Delivery Market
12.1.3 India Injectable Drug Delivery Market
12.1.4 South Korea Injectable Drug Delivery Market
12.1.5 Australia Injectable Drug Delivery Market
12.1.6 Thailand Injectable Drug Delivery Market
12.1.7 Malaysia Injectable Drug Delivery Market
12.1.8 Singapore Injectable Drug Delivery Market
12.1.9 Indonesia Injectable Drug Delivery Market
12.1.10 Phillippines Injectable Drug Delivery Market
12.1.11 Rest Of Asia-Pacific Injectable Drug Delivery Market

13 Asia-Pacific Injectable Drug Delivery Market, Company Share
13.1 Company Share Analysis: Asia-Pacific

14 Company Profiles
14.1 Becton, Dickinson And Company
14.1.1 Company Overview
14.1.1.1 Drivers Explained
14.1.1.2 Weaknesses Explained
14.1.1.3 Oppurtunities Explained
14.1.1.4 Threats Explained
14.1.2 Product Portfolio
14.1.3 Recent Developments
14.2 Pfizer
14.2.1 Company Overview
14.2.1.1 Drivers Explained
14.2.1.2 Weaknesses Explained
14.2.1.3 Oppurtunities Explained
14.2.1.4 Threats Explained
14.2.2 Product Portfolio
14.2.3 Recent Developments
14.3 Baxter International
14.3.1 Company Overview
14.3.1.1 Drivers Explained
14.3.1.2 Weaknesses Explained
14.3.1.3 Oppurtunities Explained
14.3.1.4 Threats Explained
14.3.2 Product Portfolio
14.3.3 Recent Developments
14.4 Gerresheimer Ag
14.4.1 Company Overview
14.4.2 Product Portfolio
14.4.3 Recent Developments
14.5 Schott Ag Inc.
14.5.1 Company Overview
14.5.2 Product Portfolio
14.5.3 Recent Developments
14.6 Alkermes Inc.
14.6.1 Company Overview
14.6.2 Product Portfolio
14.6.3 Recent Developments
14.7 Antares Pharma
14.7.1 Company Overview
14.7.2 Product Portfolio
14.7.3 Recent Developments
14.8 Bespak (Subsidiary Of Consort Medical Company)
14.8.1 Company Overview
14.8.2 Product Portfolio
14.8.3 Recent Developments
14.9 Elcam Medical
14.9.1 Company Overview
14.9.2 Product Portfolio
14.9.3 Recent Developments
14.10 Eli Lilly And Company
14.10.1 Company Overview
14.10.1.1 Drivers Explained
14.10.1.2 Weaknesses Explained
14.10.1.3 Oppurtunities Explained
14.10.1.4 Threats Explained
14.10.2 Product Portfolio
14.10.3 Recent Developments
14.11 Haselmeier
14.11.1 Company Overview
14.11.2 Product Portfolio
14.11.3 Recent Developments
14.12 Mylan N.V.
14.12.1 Company Overview
14.12.2 Product Portfolio
14.12.3 Recent Developments
14.13 Novo Nordisk
14.13.1 Company Overview
14.13.2 Product Portfolio
14.13.3 Recent Developments
14.14 Owen Mumford Ltd
14.14.1 Company Overview
14.14.2 Product Portfolio
14.14.3 Recent Developments
14.15 Sandoz International Gmbh
14.15.1 Company Overview
14.15.2 Product Portfolio
14.15.3 Recent Developments
14.16 Sanofi
14.16.1 Company Overview
14.16.2 Product Portfolio
14.16.3 Recent Developments
14.17 Terumo Corporation
14.17.1 Company Overview
14.17.2 Product Portfolio
14.17.3 Recent Developments
14.18 Teva Pharmaceutical
14.18.1 Company Overview
14.18.1.1 Drivers Explained
14.18.1.2 Weaknesses Explained
14.18.1.3 Oppurtunities Explained
14.18.1.4 Threats Explained
14.18.2 Product Portfolio
14.18.3 Recent Developments
14.19 West Pharmaceutical Services, Inc
14.19.1 Company Overview
14.19.2 Product Portfolio
14.19.3 Recent Developments
14.20 Ypsomed Holding Ag
14.20.1 Company Overview
14.20.2 Product Portfolio
14.20.3 Recent Developments

15 Related Reports
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Baxter International, Inc.,
  • Becton Dickinson and Company,
  • Gerresheimer AG,
  • Pfizer, Inc.,
  • Schott AG,
  • Alkermes Plc.,
  • Eli Lilly and Company,
  • Sandoz,
  • Terumo Corporation,
  • Teva Pharmaceuticals Industries Ltd.
  • Ypsomed,
  • Bespak
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll